Skip to main content
Can-Fite BioPharma Ltd. logo

Can-Fite BioPharma Ltd. — Investor Relations & Filings

Ticker · CANF ISIN · IL0010944739 LEI · 549300ZLRH6GSBOHFZ59 TA Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2026-02-17 Foreign Filer Report
Country IL Israel
Listing TA CANF

About Can-Fite BioPharma Ltd.

https://www.canfite.com/

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated drug discovery and development capabilities. The company specializes in creating orally bioavailable small-molecule drugs. Its proprietary platform technology is centered on the A3 adenosine receptor (A3AR), a therapeutic target highly expressed in cancer and inflammatory cells but minimally in normal cells. Can-Fite's compounds bind to A3AR to initiate anti-cancer and anti-inflammatory effects by modulating cellular signal transduction pathways. The company's advanced pipeline features proprietary drug candidates in Phase II and Phase III clinical development for treating oncology, inflammatory, liver, and metabolic diseases. A lead drug, Namodenoson, is in a pivotal Phase III study for advanced liver cancer.

Recent filings

Filing Released Lang Actions
6-K Filing
Foreign Filer Report
2026-02-17 English
Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filing submitted to the SEC by Can-Fite BioPharma Ltd. A Form 6-K is a standard regulatory filing used by foreign private issuers to report material events. In this specific instance, the document serves to announce and furnish a press release regarding a Canadian patent allowance for one of the company's drug candidates (Namodenoson). Since the document is a general regulatory filing that does not fit into more specific categories like financial reports or shareholder voting results, it is classified as a Regulatory Filing (RNS).
2026-02-09 English
Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Regulatory Filings Classification · 1% confidence The document is a short regulatory filing from the Israel Securities Authority (MAGNA system) that explicitly states 'The corporation scheduled the publication of the report' and 'Attached hereto is a report on...'. Because the document serves as a notification of a report being released rather than the report itself, and it is under the character limit, it falls under the Report Publication Announcement (RPA) category.
2026-02-09 English
6-K Filing
Foreign Filer Report
2026-02-09 English
Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filed with the SEC by Can-Fite BioPharma Ltd. A Form 6-K is a standard regulatory filing used by foreign private issuers to report material information, such as press releases, to the SEC. While the document contains a press release regarding a clinical observation, the filing itself is a formal regulatory submission. According to the provided definitions, 'Regulatory Filings' (RNS) serves as the fallback category for miscellaneous filings that do not fit into more specific categories like earnings releases or annual reports.
2026-02-05 English
Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
Regulatory Filings Classification · 1% confidence The document is a short regulatory filing from Can-Fite Biopharma Ltd submitted to the Israel Securities Authority. It explicitly states 'The corporation scheduled the publication of the report to 05/02/2026' and provides a link to an attached PDF file regarding a clinical trial update. Per the 'Menu vs Meal' rule, since this is a short announcement notifying the public of the publication of a report, it is classified as a Report Publication Announcement (RPA).
2026-02-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.